Idoroenyi Amanam to Transplantation Conditioning
This is a "connection" page, showing publications Idoroenyi Amanam has written about Transplantation Conditioning.
Connection Strength
1.896
-
Disability-Free Survival: A Novel Morbidity Endpoint for Older Adult Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther. 2026 Jul; 32(7):877.e1-877.e11.
Score: 0.242
-
Long-term survival outcomes of allo-HCT in AML with fludarabine/melphalan conditioning and tacrolimus/sirolimus GVHD prophylaxis. Bone Marrow Transplant. 2026 01; 61(1):82-91.
Score: 0.236
-
Outcomes after Melphalan-Based Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Renal Impairment. Transplant Cell Ther. 2025 Oct; 31(10):824.e1-824.e13.
Score: 0.230
-
Melphalan-based conditioning with post-transplant cyclophosphamide for peripheral blood stem cell transplantation: donor effect. Bone Marrow Transplant. 2025 May; 60(5):625-631.
Score: 0.224
-
Fludarabine melphalan reduced intensity conditioning vs radiation-based myeloablative conditioning in patients undergoing allogeneic transplantation for acute myeloid leukemia with measurable residual disease. Bone Marrow Transplant. 2025 02; 60(2):165-174.
Score: 0.221
-
Comparing transplant outcomes in ALL patients after myeloablative conditioning in mismatch-related or unrelated donor settings. Bone Marrow Transplant. 2024 Nov; 59(11):1542-1551.
Score: 0.216
-
Total Body Irradiation and Fludarabine with Post-Transplantation Cyclophosphamide for Mismatched Related or Unrelated Donor Hematopoietic Cell Transplantation. Transplant Cell Ther. 2024 10; 30(10):1013.e1-1013.e12.
Score: 0.216
-
Chronic GVHD: review advances in prevention, novel endpoints, and targeted strategies. Hematology Am Soc Hematol Educ Program. 2023 12 08; 2023(1):164-170.
Score: 0.206
-
Impact of spliceosome mutation on outcomes of myelodysplastic syndrome and chronic myelomonocytic leukemia patients undergoing allogeneic hematopoietic cell transplantation. Leuk Res. 2024 10; 145:107565.
Score: 0.054
-
Tocilizumab for Cytokine Release Syndrome Management After Haploidentical Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis. Transplant Cell Ther. 2023 08; 29(8):515.e1-515.e7.
Score: 0.050